Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 19.42% is 194% above its 4-year average of -20.60%, around the middle of its 4-year range (-325.81%–264.38%).
40.14% below its 12-month average of 32.44%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 27.32%.
GROSS MARGIN
19.42%
GROSS MARGIN AVG TTM
32.44%
GROSS MARGIN AVG 3Y
28.82%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-40.14%
CURRENT VS 3Y AVG
-32.61%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-52.87%
vs the sector median at left
60 Degrees Pharmaceuticals, Inc.
Market Cap
$3.90M
Gross Margin
19.42%
TTM Avg
32.44%
3Y Avg
28.82%
5Y Avg
N/A
Market Cap
$3.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
-19.05%
Market Cap
$3.65M
Gross Margin
0.00%
TTM Avg
41.76%
3Y Avg
-40.89%
5Y Avg
-27.26%
Market Cap
$3.63M
Gross Margin
23.81%
TTM Avg
23.81%
3Y Avg
26.43%
5Y Avg
24.11%
Market Cap
$4.21M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.53M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $3.90M | 19.42% | 32.44% | 28.82% | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | 0.00% | 0.00% | 25.00% | -19.05% |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A | 0.00% | 0.00% | 0.00% |
| Evogene Ltd. (EVGN)vs › | $3.65M | -6.25% | 25.54% | 36.71% | 34.86% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | 0.00% | 41.76% | -40.89% | -27.26% |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | 23.81% | 23.81% | 26.43% | 24.11% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | 0.00% | 0.00% | 0.00% | 0.00% |
| Moolec Science S.A. (MLEC)vs › | $3.50M | 34.17% | 21.29% | 6.69% | 5.35% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
Gross Margin
19.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 27.32% |
| 2026-03-31 | 47.12% |
| 2025-12-31 | 60.22% |
| 2025-09-30 | -22.87% |
| 2025-06-30 | 50.41% |
| 2025-03-31 | 55.20% |
| 2024-12-31 | 54.84% |
| 2024-09-30 | 17.45% |
| 2024-06-30 | 28.33% |
| 2024-03-31 | 38.08% |
| 2023-12-31 | -242.47% |
| 2023-09-30 | -39.09% |
| 2023-06-30 | -209.04% |
| 2023-03-31 | -325.81% |
| 2022-12-31 | 264.38% |
| 2022-09-30 | 45.13% |
| 2022-06-30 | -92.86% |
| 2022-03-31 | -91.68% |
| 2021-12-31 | -76.30% |
